Salta al contenuto principale
Passa alla visualizzazione normale.


Open Radical Nephrectomy: 35 Years of Experience at the "Luciano Giuliani" Urological Department of the University of Genoa

  • Autori: Carmignani, G.; Simonato, A.; Corbu, C.; Traverso, P.; Ruggiero, G.; Pizzorno, R.; Vota, P.; Martorana, G.; Belgrano, E.; Romagnoli, A.
  • Anno di pubblicazione: 2006
  • Tipologia: Articolo in rivista
  • OA Link:


Objective: Radical nephrectomy remains the gold standard for surgically resectable kidney neoplasms > 4 cm and, in selected cases, also in presence of metastatic disease. We reviewed the records of the patients having surgery at the University of Genoa in the last 35 yr. Methods: We have retrospectively assessed all the radical nephrectomies performed between 1970 and 2005. Among tumours of the kidney subjected to surgical treatment during this period, we found 1105 cases of histologically proven renal cell carcinoma (RCC), 965 of which had records available for the study. The number of cases per year, symptoms at diagnosis, surgical strategy, staging of the tumour, and survival were reviewed. Results: Among 965 patients, radical nephrectomy was performed in 825 (85.5%) with a mean age of 61.26 yr (range, 20-88 yr) and partial nephrectomy in 140 (14.5%) with a mean age of 59.4 yr (range, 20-86 yr). Metastases at diagnosis were present in 81 patients (9.8%). The surgical approach was transperitoneal in 484 (58.6%) and extraperitoneal in 341 (41.4%) of the 825 patients. A transperitoneal approach was preferred for all tumours > 10 cm in diameter. No postoperative deaths occurred due to technical complications but 15 patients (1.8%) died in the 30 d following the operation due to myocardial infarction, pulmonary embolus, or sepsis. At the last follow-up, the 5-yr overall survival rate was 56% and the 5-yr cancer-specific survival and disease-free survival rates were 70% and 65%, respectively. Conclusions: The incidence of RCC has slowly increased in recent years in our department. Surgical extirpation remains the most widely accepted and potentially curative treatment option for renal neoplasms with a good efficacy and low mortality and morbidity rates. (c) 2006 Published by Elsevier B.V. on behalf of European Association of Urology.